CME Group will list Avalanche and Sui futures on 4 May, extending its regulated crypto derivatives lineup to nine assets as the exchange prepares to move all digital asset products to round-the-clock trading later that month.
CME Group will list Avalanche and Sui futures on 4 May, extending its regulated crypto derivatives lineup to nine assets as the exchange prepares to move all digital asset products to round-the-clock trading later that month.
The new contracts come in standard and micro sizes — 5,000 AVAX and 500 AVAX for Avalanche; 50,000 SUI and 5,000 SUI for Sui — and are cash-settled against CME CF reference rates tied to New York settlement windows. Both will clear through CME's central counterparty, the same infrastructure that backstops its bitcoin and ether futures, which between them have attracted hundreds of billions in notional volume since launching in 2017 and 2021 respectively.
The listing is pending regulatory review, which at this point reads as procedural rather than uncertain. CME has followed the same playbook for every crypto addition since Solana futures went live earlier this year: file, announce, and let the comment period run. No crypto futures filing from the exchange has been rejected to date.
What makes the timing worth watching is where it sits relative to CME's broader infrastructure shift. On 29 May — less than four weeks after AVAX and SUI go live — the exchange will begin offering [24/7 crypto futures and options trading](/news/cme-group-to-launch-24-7-crypto-futures-and-options-trading-on-29-may-in-landmark-institutional-shift/), eliminating the overnight and weekend gaps that have long pushed institutional flow toward unregulated offshore venues. The AVAX and SUI contracts will initially trade on CME Globex during standard hours before transitioning to the continuous schedule.
The selection of Avalanche and Sui tells a story about where institutional interest is heading. Both are layer-1 networks that have leaned heavily into real-world asset tokenisation and institutional DeFi — the two narratives that have attracted the most serious capital in 2026. Avalanche's subnet architecture has been adopted by several tokenised fund issuers, while Sui's object-oriented data model has drawn attention from payments companies looking for sub-second finality without the gas fee volatility of Ethereum mainnet.
CME's crypto suite now covers Bitcoin, Ether, Solana, XRP, Cardano, Chainlink, Stellar, Avalanche, and Sui. The breadth matters less than the pattern: every addition has preceded or coincided with a spot ETF filing for the same asset. Solana futures launched in February; a spot SOL ETF application followed within weeks. The same dynamic played out with XRP. CME's reference rates serve as the pricing backbone for most US-listed crypto ETFs, and having a regulated futures market is widely considered a prerequisite — or at least a strong signal — for SEC approval of a spot product.
For Avalanche holders, the futures listing provides a hedging mechanism that didn't previously exist in a regulated venue. Institutional desks that want AVAX exposure without touching the spot token can now take positions through the same prime brokerage relationships they use for everything else. The micro contracts, sized to keep notional values manageable at current prices, are designed to attract smaller funds and retail-facing brokers who route through [CME's existing infrastructure](/news/cme-group-launches-bitcoin-futures-trading/).
The Sui listing carries its own momentum. SUI has rallied roughly 30 per cent since late March, partly on anticipation of the CME announcement and partly on growing developer activity around its Move-based smart contract language. Whether the futures listing accelerates that trend or provides a convenient tool for profit-taking will depend on what side of the trade institutional desks choose to take first.
The 4 May date puts CME ahead of several competing exchanges that have signalled interest in alternative layer-1 derivatives but haven't filed. In a market where first-mover advantage in regulated products can lock in liquidity for years, the lead matters — and CME clearly intends to keep it.
